Business Context and Reporting Period
This Form 8-K was filed by Wave Life Sciences Ltd. on March 8, 2016. The report addresses Item 5.02(e) regarding the approval of compensatory arrangements for certain executive officers by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved the following changes effective January 1, 2016:
- Paul B. Bolno, M.D. (President and CEO): Annual base salary increased from $450,000 to $490,000. Annual target bonus percentage increased from 25% to 50%.
- Chandra Vargeese, Ph.D. (SVP, Head of Drug Discovery): Annual base salary increased from $285,000 to $315,000. Annual target bonus percentage increased from 25% to 35%.
- Christopher Francis, Ph.D. (VP, Head of Business Development): Annual target bonus percentage increased from 25% to 35%.
- Kyle Moran (VP, Head of Finance): Annual target bonus percentage increased from 25% to 35%.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The compensation increases were approved with the benefit of market-based compensation data prepared by an independent consultant.
Investor Verification Points
- Verify the effective date of the salary and bonus changes (January 1, 2016) against the company's fiscal calendar.
- Review the total compensation impact on the company's operating expenses for the 2016 fiscal year.
- Confirm the specific market-based data used by the independent compensation consultant to justify the increases.